August 20, 2025 — Leads & Copy — Rezolute, Inc. (Nasdaq: RZLT), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), has appointed Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025.
Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, expressed enthusiasm for Karnawat’s arrival, citing his track record of successfully launching therapies across multiple therapeutic areas, including four ultra-rare disease launches at Ultragenyx. Elam emphasized that Karnawat’s leadership will be instrumental as they advance toward commercialization and build a commercial organization to deliver their therapy.
Karnawat brings over 25 years of experience in global commercialization of biopharmaceuticals and medical devices. Before joining Rezolute, he held Vice President positions at Cytokinetics and Ultragenyx, where he led key commercial functions in launching ultra-rare disease products, including Crysvita. He also led Market Access teams at Myriad Genetics and Vivus Pharmaceuticals and held leadership roles at Novo Nordisk and LifeScan.
Karnawat holds an MBA from the Wharton School of Business at the University of Pennsylvania, a Ph.D. and an M.S. in Engineering from North Dakota State University, and a B.E. in Civil Engineering from the College of Engineering in Pune, India.
In connection with Karnawat’s appointment, the Company’s Board of Directors approved the grant of an inducement stock option of 275,000 shares of the Company’s common stock in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price of $6.55 per share. The stock options will vest and become exercisable as to 25% of the underlying shares on the first anniversary of the grant date, and will vest and become exercisable as to the remaining 75% of the underlying shares in 36 equal monthly installments from the first anniversary of the grant date, subject to his continued employment with Rezolute on such vesting dates. If the Company is acquired during his employment, all remaining options will automatically vest.
Dr. Karnawat stated he is honored to join Rezolute and looks forward to working alongside the team to bring this important therapy to patients, families, and physicians around the world.
Christen Baglaneas, cbaglaneas@rezolutebio.com, 508-272-6717
Source: Rezolute, Inc.
